International Experience and Implications of Real-World Evidence Supporting Drug Medical Insurance Access

doi:10.19546/j.issn.1674-3830.2024.7.003

China Health Insurance ›› 2024, Vol. 0 ›› Issue (7) : 24-32. DOI: 10.19546/j.issn.1674-3830.2024.7.003

Special Topic Analysis

International Experience and Implications of Real-World Evidence Supporting Drug Medical Insurance Access

Author information +

History +

Abstract

Objective: This study investigates the application of real-world evidence (RWE) in decision-making of drug medical insurance access in major countries, in order to provide evidence and support for the dynamic adjustment of the China’s national medical insurance drug catalog. Methods: A comprehensive literature review was conducted to systematically summarize the current experience of RWE in supporting drug access decision-making in major countries, including the United Kingdom, France, Germany, Italy, Australia, the United States, and Canada. Results: This study focuses on summarizing the application scenarios and specific practice of RWE in drug medical insurance access decision-making in major countries. Based on China’s practice, relevant suggestions are proposed for RWE to support the adjustment of national medical insurance drug catalog. Conclusions: RWE plays an increasingly important role in drug medical insurance access decision-making. By considering China’s national conditions and practical experience, and drawing upon the experience of major countries, a scientific pathway for RWE to support drug medical insurance access decision-making with Chinese characteristics should be explored.

Key words

real-world evidence / medical insurance decision-making / drug access / international experience

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

International Experience and Implications of Real-World Evidence Supporting Drug Medical Insurance Access[J]. China Health Insurance. 2024, 0(7): 24-32 https://doi.org/10.19546/j.issn.1674-3830.2024.7.003

References

[1] BLONDE L, KHUNTI K, HARRIS S B, et al.Interpretation and impact of real-world clinical data for the practicing clinician[J]. Advances in therapy, 2018, 35(11): 1763-1774.
[2] 中国抗癌协会肿瘤大数据与真实世界研究专业委员会.肿瘤大数据与真实世界研究中国专家共识(2022版)[J].中华肿瘤杂志, 2022, 44(12): 1330-1343.
[3] NICE. Regorafenib for previously treated metastatic colorectal cancer[EB/OL].(2023-02-08)[2024-07-14]. https://www.nice.org.uk/guidance/ta866.
[4] NICE. Fenfluramine for treating seizures associated with Dravet syndrome[EB/OL].(2022-07-08)[2024-07-14]. https://www.nice.org.uk/guidance/ta808.
[5] MAKADY A, HAM R TEN, DE BOER A, et al.Policies for use of real-world data in health technology assessment (HTA): a comparative study of six hta agencies[J]. Value in health, 2017, 20(4): 520-532.
[6] ICER. Value Assessment Framework[J].2023.
[7] ROBINSON M F, MIHALOPOULOS C, MERLIN T, et al.Characteristics of managed entry agreements in Australia[J]. International journal of technology assessment in health care, 2018, 34(1): 46-55.
[8] LEAHY T P, RAMAGOPALAN S, SAMMON C.The use of UK primary care databases in health technology assessments carried out by the National Institute for Health and Care Excellence (NICE)[J]. BMC health services research, 2020, 20(1): 675.
[9] SEIDEL K, SCHNAIDT S, VIERING T, et al.10 years of AMNOG: importance of real world evidence studies in the German benefit assessment process[J]. 2022.
[10] DUFFIELD S, JONSSON P.The real-world impact of National Institute for Health and Care Excellence’s real-world evidence framework[J]. Journal of comparative effectiveness research, 2023, 12(11): e230135.
[11] PBAC. PBAC guidelines version 5.0[EB/OL].(2016-09)[2024-06-12]. https://pbac.pbs.gov.au/information/about-the-guidelines.html.
[12] NICE. NICE real-world evidence framework[EB/OL].(2022-06-23)[2024-06-12]. https://www.nice.org.uk/corporate/ecd9/resources/nice-realworld-evidence-framework-pdf-1124020816837.
[13] AIFA. Application for reimbursement and priing[EB/OL].(2020-12-23)[2024-06-11]. https://www.aifa.gov.it/domanda-rimborsabilita-e-prezzo.
[14] CHAN K, NAM S, EVANS B, et al.Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration[J]. BMJ Open, 2020, 10(1): e032884.
[15] HAS. Doctrine de la commission de la transparence (CT)[EB/OL].(2023-02-17)[2024-06-12]. https://www.has-sante.fr/jcms/c_412210/fr/commission-de-la-transparence.
[16] IQWiG. General methods version 7.0[EB/OL].(2023-09-19)[2024-06-12]. https://www.iqwig.de/methoden/general-methods_version-7-0.pdf.
[17] DE POUVOURVILLE G, CUNNINGHAM D, FRICKE FU, et al.Across-country variations of real-world data and evidence for drugs: a 5-European-country study[J]. Value in health, 2023, 26(4S): 3-10.
[18] GHOSH R E, CRELLIN E, BEATTY S, et al.How clinical practice research datalink data are used to support pharmacovigilance[J]. Therapeutic advances in drug safety, 2019 (10): 2042098619854010.
[19] 袁妮,周娜,杨勇,等.英国罕见病药物准入过程中价格谈判机制的实施经验及启示[J].中国新药杂志,2020,29(5): 481-486.
[20] 刘跃华,刘昭,张萌,等.英国癌症药物基金改革及对医保创新药支付政策的启示[J].中国卫生政策研究,2020,13(7): 52-57.
[21] 李伟,施慧,丁锦希,等.英国癌症药物基金的疗效风险分担协议分析[J].中国新药杂志,2021, 30(17):1559-1564.
[22] JORGENSEN J, HANNA E, KEFALAS P.Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries[J]. Journal of market access and health policy, 2020, 8(1): 1715536.
[23] JORGENSEN J, KEFALAS P.The use of innovative payment mechanisms for gene therapies in Europe and the USA[J]. Regenerative medicine, 2021, 16(4): 405-422.
[24] XOXI E, FACEY K M, CICCHETTI A.The evolution of AIFA registries to support managed entry agreements for orphan medicinal products in Italy[J]. Frontiers in pharmacology, 2021, (12): 699466.
[25] TROTTA F, GUERRIZIO M A, DI FILIPPO A, et al.Financial outcomes of managed entry agreements for pharmaceuticals in Italy[J]. JAMA health forum, 2023, 4(12): e234611.
[26] 汤静琪,张晓.澳大利亚高值药物管理准入政策及对我国的启示[J].中国新药杂志, 2021, 30(12): 1073-1078.
[27] CIBMTR. CIBMTR to Track Long-Term Outcomes Data for Kymriah®[EB/OL].(2018-09-14)[2024-06-11]. https://cibmtr.org/Files/News-Releases/CIBMTR-Novartis-Press-Release-FINAL.pdf.
[28] CIBMTR. CIBMTR announces collaboration with kite to track long-term outcomes data for Yescarta®[EB/OL].(2018-05-17)[2024-06-12]. https://cibmtr.org/Files/News-Releases/MCW__BTMB_CIBMTR-Press-Release-FINAL.pdf.
[29] CIBMTR. Kite and the Cibmtr® present positive findings from real-world use of Yescarta® (axicabtagene ciloleucel) in relapsed or refractory large b-cell lymphoma[EB/OL].(2019-12-09)[2024-06-12]. https://cibmtr.org/Files/News-Releases/CIBMTR-Kite-Press-Release-FINAL.pdf.
[30] JUGNA SHAH. Achieving sustainable market and patient access: medicare and medicaid coverage, reimbursement,coding issues for CAR-T[EB/OL].(2019-04-28)[2024-06-12]. https://www.asgct.org/ASGCT/media/about/Approved-Jugna-Shah-from-Nimitt_ASGCT_Final-CAR-T-Presentation-for-Distribution.pdf.
[31] CIBMTR. Center for International Blood &Marrow Transplant Research (CIBMTR) Form4100 R9.0: cellular therapy essential data follow-up form (2023)[EB/OL].(2023-07-28)[2024-06-12]. https://cibmtr.org/Data-Collection-Files/Forms/4100-R9-.pdf.
[32] PULINI A A, CAETANO G M, CLAUTIAUX H, et al.Impact of real-world data on market authorization, reimbursement decision and price negotiation[J]. Therapeutic innovation and regulatory science, 2021, 55(1): 228-238.
[33] 谢金平,邵蓉.法国卫生技术评估和定价与偿付政策研究及对我国的启示[J]. 中国医疗保险, 2020(8): 65-70.
[34] FERNANDEZ J, TARANSAUD J, PINET M, et al.Bilan rétrospectif des études post-inscription de la commission de la transparence : quelle prise en compte des résultats?[J]. Revue d’Épidémiologie et de Santé Publique, 2016, 64: S304.
[35] HAS. HAS unveils its action plan for innovative medicines[EB/OL].(2020-01-27)[2024-06-10]. https://www.has-sante.fr/jcms/p_3148262/en/has-unveils-its-action-plan-for-innovative-medicines.
[36] IQWiG. Development of scientific concepts for the generation of routine practice data and their analysis for the benefit assessment of drugs according to §35a Social Code Book V-rapid report[EB/OL].(2020-05-14)[2024-06-12]. https://www.iqwig.de/en/projects/a19-43.html.
[37] IQWiG. Concept for routine practice data collection-marstacimab (haemophilia A and B)[EB/OL].(2024-04-11)[2024-06-12]. https://www.iqwig.de/en/projects/a24-39.html.
[38] IQWiG. Concept for routine practice data collection-fidanacogene elaparvovec (haemophilia B)[EB/OL].(2024-10-09)[2024-06-12]. https://www.iqwig.de/en/projects/a23-97.html.
[39] IQWiG. Concept for routine practice data collection-Odronextamab (relapsed or refractory DLBCL)[EB/OL].(2024-02-08)[2024-06-12]. https://www.iqwig.de/en/projects/a24-18.html.
[40] IQWiG. Concepts for the generation of routine practice data and their analysis for the benefit assessment of drugs according to §35a Social Code Book V[J]. 2020.
[41] Canadian Centre for Applied Research in Cancer Control. Developing a framework for incorporating real-world evidence into drug funding decisions: CanREValue Collaboration Policy Working Groups Final Report2024[EB/OL].(2024-02)[2024-06-14]. https://cc-arcc.ca/wp-content/uploads/2024/02/CanREValue-Policy-WG-Final-Report-2024_V4.0-FINAL.pdf.
[42] CanREValue Policy WG. Final Report 2024_V4.0 FINAL[EB/OL].(2024-02)[2024-06-07]. https://cc-arcc.ca/canrevalue-kt/canrevalue-policy-wg-final-report-2024_v4-0-final.